AndroGel Geriatric (65+) Monitoring: Lab Tests, Safety Checks, and Dose Adjustments

Why Geriatric Monitoring Differs from Standard TRT Oversight

Older men on testosterone replacement therapy face a different risk profile than men in their 40s or 50s. Declining renal clearance, higher baseline cardiovascular disease prevalence, and polypharmacy all shift the monitoring calculus. The Endocrine Society's 2018 clinical practice guideline explicitly recommends against prescribing testosterone to men over 65 solely for age-related decline without confirmed hypogonadism and symptoms, and stresses "a formalized monitoring plan" for those who do receive treatment.

The T-Trials (N=790 men aged 65+) confirmed that daily topical testosterone normalized serum levels and improved sexual function, mood, and walking distance over 12 months 1. Those same trials also revealed a statistically significant increase in coronary artery plaque volume in the testosterone group versus placebo, a finding that makes cardiovascular vigilance especially important in geriatric patients 2. That result does not prohibit use. It means you monitor harder.

The 2023 TRAVERSE trial (N=5,246, mean age 63 to 20% aged 70+) provided longer-term reassurance: testosterone treatment did not increase the composite rate of major adverse cardiovascular events (MACE) over a median follow-up of 33 months compared with placebo 3. TRAVERSE did not eliminate concern entirely, though. Pulmonary embolism incidence was higher in the testosterone arm (0.9% vs. 0.5%), reinforcing the need for hematocrit surveillance.

Baseline Labs Before Starting AndroGel

Every man 65 or older should have a complete workup before the first application of AndroGel. Skipping baseline labs makes subsequent monitoring meaningless because you have no reference values to compare against.

Minimum baseline panel: two morning total testosterone levels (drawn before 10 AM on separate days), free testosterone (calculated or measured by equilibrium dialysis), complete blood count with hematocrit, comprehensive metabolic panel including creatinine and eGFR, fasting lipid panel, PSA, and a digital rectal exam 4. The Endocrine Society recommends confirming testosterone below 300 ng/dL on two occasions before diagnosing hypogonadism. A liver function panel is prudent given that older men are more likely to be on hepatotoxic co-medications such as statins or acetaminophen at regular doses.

Optional but recommended: baseline DXA if the patient has a prior fragility fracture or is on chronic glucocorticoids, baseline ECG if the patient has known coronary artery disease or multiple cardiovascular risk factors, and hemoglobin A1c if the patient has prediabetes or type 2 diabetes. Testosterone therapy can lower fasting glucose and insulin resistance in hypogonadal men with type 2 diabetes, which may require downward adjustment of diabetes medications to prevent hypoglycemia.

Hematocrit: The Single Most Dangerous Lab to Miss

Testosterone stimulates erythropoiesis. That is pharmacology, not a side effect. In older men with already-reduced plasma volume from age-related dehydration and diuretic use, even modest erythrocytosis raises viscosity and thromboembolic risk. The FDA's 2015 label revision for testosterone products includes polycythemia as a known risk.

The American Urological Association sets a hard stop at hematocrit above 54% 5. At that threshold, hold AndroGel, confirm the value on repeat, and do not restart until hematocrit drops below 50%. A meta-analysis of 15 randomized trials found that testosterone therapy increased absolute hematocrit by a mean of 2.8 percentage points, with topical formulations causing less polycythemia than injectable esters 6.

Monitoring schedule for hematocrit: check at baseline, 3 months, 6 months, 12 months, then every 6 to 12 months indefinitely. Men taking loop diuretics or with COPD-related baseline erythrocytosis need more frequent checks, roughly every 8 to 12 weeks during the first year. A practical threshold for concern is any single-visit rise of more than 3 points from baseline, even if the absolute value is still below 54%.

PSA and Prostate Surveillance

Testosterone does not cause prostate cancer. That myth originates from a misinterpretation of Charles Huggins' 1941 castration data. A 2016 meta-analysis in Medicine (N=4,073) found no significant increase in prostate cancer incidence among testosterone-treated men versus placebo. What testosterone can do is grow an existing occult cancer faster and raise PSA in the first 6 to 12 months of therapy even without malignancy.

For men 65 and older, the Endocrine Society recommends checking PSA at baseline, 3 months, and 12 months, then annually 4. A PSA rise exceeding 1.4 ng/mL within 12 months of starting testosterone, a PSA velocity above 0.4 ng/mL per year, or any confirmed PSA above 4.0 ng/mL should trigger a urology referral. Digital rectal exam remains part of the annual assessment.

Men with a history of Gleason 6 prostate cancer treated with radical prostatectomy and undetectable PSA for 2+ years may still be candidates for testosterone therapy, according to a retrospective cohort study in the Journal of Urology (N=82), but this decision requires close collaboration with a urologist. The monitoring interval for these patients should be shortened to every 3 months for at least 2 years.

Cardiovascular Monitoring in Geriatric Patients

The T-Trials' cardiovascular substudy showed a net increase in noncalcified coronary artery plaque volume of 41 mm³ vs. 34 mm³ in placebo over 12 months 2. TRAVERSE later found no increased MACE risk over 33 months, but the trial excluded men with recent MI, stroke, or NYHA Class III/IV heart failure 3. Men 65+ often fall outside that trial's inclusion window.

Dr. Shalender Bhasin, principal investigator of TRAVERSE and Professor of Medicine at Harvard Medical School, stated: "The TRAVERSE results should not be extrapolated to men with unstable cardiovascular conditions, who were excluded from the trial."

Practical cardiovascular monitoring: blood pressure at every visit, fasting lipid panel at 6 and 12 months then annually, and a review of cardiovascular symptoms (chest pain, dyspnea on exertion, leg swelling) at each follow-up. If the patient has known atherosclerotic cardiovascular disease, coordinate with cardiology before initiating AndroGel and after any dose change. Testosterone can decrease HDL cholesterol by 4 to 5 mg/dL, per the T-Trials lipid data, a shift that may matter more in older men already on borderline profiles.

Renal Function and Dose Adjustment Considerations

Age-related glomerular filtration rate decline averages roughly 1 mL/min/1.73 m² per year after age 40, per KDIGO guidelines. Testosterone gel is metabolized hepatically and excreted renally as glucuronide and sulfate conjugates. While AndroGel's prescribing information does not mandate dose reduction in renal impairment, impaired clearance can shift steady-state levels higher than expected, particularly in men with eGFR below 45.

Check eGFR at baseline and every 6 months. If eGFR drops below 30 mL/min/1.73 m² during therapy, recheck serum testosterone and free testosterone to ensure levels have not risen above the therapeutic range. Fluid retention from testosterone can worsen edema in men with Stage 4 or 5 CKD. The Endocrine Society guideline recommends caution in patients with severe renal insufficiency and advises against testosterone use in men with uncontrolled congestive heart failure, which often co-occurs with advanced CKD in geriatric patients.

Polypharmacy and Drug Interaction Burden

Men aged 65+ take a median of 5 prescription medications according to CDC NCHS data. Testosterone interacts meaningfully with several drug classes common in this population.

Warfarin is the highest-priority interaction. Testosterone increases warfarin's anticoagulant effect, raising INR unpredictably 4. Check INR within 1 week of starting AndroGel and monthly for the first 3 months. Insulin and oral hypoglycemics require glucose monitoring intensification because testosterone may improve insulin sensitivity. Corticosteroids compound fluid retention risk.

A full medication reconciliation at every testosterone-related visit is not optional in geriatric patients. It takes 3 minutes and prevents dangerous gaps. Pay particular attention to newly added medications between visits, especially anticoagulants, antihypertensives, and CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) that can alter testosterone metabolism through their effect on hepatic enzyme activity.

Bone Density Monitoring

One of the T-Trials' secondary findings was that 12 months of testosterone gel increased volumetric bone mineral density at the spine by 7.5% and at the hip by 3.0% in men 65 and older with low bone density at baseline 7. This is a meaningful skeletal benefit for a population at high fracture risk.

Obtain a baseline DXA scan if the patient has a history of fragility fracture, chronic glucocorticoid use (5 mg prednisone equivalent for 3+ months), or a T-score below minus 1.5 on any prior scan. Repeat DXA at 12 to 24 months to assess response. If bone density does not improve or continues to decline despite normal testosterone levels, evaluate for coexisting causes: vitamin D deficiency, hyperparathyroidism, myeloma, or non-adherence to therapy.

Falls risk assessment is equally important. Testosterone may improve muscle mass and physical function, which could reduce fall frequency, but the T-Trials found only a modest improvement in 6-minute walking distance (an increase of 6.0 meters vs. placebo) 1. Do not rely on testosterone alone for falls prevention. Physical therapy referral and home safety evaluation should happen in parallel.

When to Deprescribe Testosterone in Older Men

Not every man who starts AndroGel at 66 should still be on it at 78. The concept of deprescribing, systematically reducing or stopping medications that may no longer provide net benefit, applies directly to testosterone therapy in aging men.

The Endocrine Society states: "If a patient has not experienced improvement in symptoms after a 6-month adequate trial, clinicians should consider discontinuing testosterone therapy" 4. Beyond the initial trial period, reassess annually whether the original indication still applies and whether new contraindications have developed.

Triggers for stopping or reducing AndroGel in geriatric patients: hematocrit persistently above 50% despite dose reduction, new diagnosis of hormone-sensitive cancer (prostate or breast), PSA velocity exceeding 0.4 ng/mL per year, new or worsening heart failure, severe untreated sleep apnea (testosterone can worsen obstructive sleep apnea), and patient preference after shared decision-making.

Taper is not pharmacologically required for topical testosterone. Abrupt cessation is physiologically safe because AndroGel has a short half-life and does not suppress the hypothalamic-pituitary-gonadal axis as profoundly as injectable esters in older men who already have primary hypogonadism. Recheck testosterone 4 to 6 weeks after stopping to confirm return to baseline.

Monitoring Schedule Summary for Clinicians

A condensed monitoring timeline that a geriatric provider can tape to a chart:

Baseline (before first application): Two morning testosterone levels, CBC with hematocrit, CMP with eGFR, fasting lipids, PSA, DRE, medication reconciliation, cardiovascular risk assessment.

Month 3: Trough total testosterone (2 to 8 hours post-application), hematocrit, PSA, INR (if on warfarin), symptom reassessment, medication reconciliation.

Month 6: Total testosterone, hematocrit, fasting lipids, eGFR, PSA, blood pressure, symptom reassessment.

Month 12: Full repeat of baseline panel, DXA if indicated, DRE, formal deprescribing assessment.

Annually thereafter: Total testosterone, hematocrit, PSA, DRE, fasting lipids, eGFR, medication reconciliation, deprescribing review. Shorten any interval if a new interacting medication is added or clinical status changes.

The AUA recommends testosterone trough levels between 450 and 600 ng/dL for symptom optimization, while the Endocrine Society targets the mid-normal range of 400 to 700 ng/dL 4 5. In men 65+, aiming for the lower half of these ranges (400 to 550 ng/dL) minimizes erythrocytosis risk while still providing symptomatic benefit.